| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2025 ( Subtotal = $2,712,491 ) |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 00 | 24 | HRSA | 3/6/2025 | $129,999 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 002 | 3 | NIH | 12/23/2024 | $78,125 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 000 | 4 | NIH | 1/21/2025 | $482,604 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00HL153896 | YAP1, neointima formation, and blood pressure regulation | 000 | 5 | NIH | 11/27/2024 | $249,000 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 000 | 1 | NIH | 1/24/2025 | $636,185 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA288278 | Molecular basis and targeting of FASN in expanding PARPi utility for TNBC | 000 | 1 | NIH | 12/19/2024 | $524,419 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03ES036303 | SWI/SNF in ultraviolet radiation-induced chromatin alterations | 000 | 1 | NIH | 12/19/2024 | $156,250 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 002 | 3 | NIH | 4/24/2025 | $118,756 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 001 | 4 | NIH | 4/24/2025 | $53,623 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 001 | 3 | NIH | 3/25/2025 | $217,702 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00DA055064 | Investigating the long-term effects of prenatal circadian rhythm disruption on substance use-related disorders | 000 | 3 | NIH | 3/4/2025 | $248,996 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01NS122534 | Pre and post-synaptic pathways underlying the stress response in the adrenal medulla | 000 | 10 | NIH | 4/10/2025 | $370,154 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK134053 | Role of neutrophil extracellular traps (NETs) in Inflammatory bowel disease | 000 | 3 | NIH | 2/20/2025 | $387,115 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21AG091047 | Mechanistic tRNA modification affects to aging | 000 | 1 | NIH | 11/14/2024 | $430,603 |
| 2025 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 001 | 1 | NIH | 4/10/2025 | -$636,185 |
| 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 01 | 14 | HRSA | 3/31/2025 | $0 |
| 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 001 | 2 | NIH | 12/20/2024 | $14,777 |
| 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HL152162 | Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine | 000 | 4 | NIH | 4/24/2025 | $0 |
| 2025 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA230744 | Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis | 000 | 6 | NIH | 1/9/2025 | $0 |
| 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21MH127500 | The effect of SHANK3 mutation in transgenic prairie voles on natural social behaviors and genetic mechanisms | 000 | 2 | NIH | 4/8/2025 | -$6,970 |
| 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21MH125277 | A large sample machine learning network analysis of vertex cortical thickness measures for high resolution definition of PTSD related cortical structure abnormalities | 000 | 2 | NIH | 1/13/2025 | $0 |
| 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R35GM150588 | Control of Klebsiella capsule biosynthesis and attachment | 000 | 1 | NIH | 2/28/2025 | -$180,607 |
| 2025 | 2023 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | K01AA029763 | Targeting PI3K/BRD4 and Hedgehog Pathway in Alcohol Associated Liver Disease | 002 | 4 | NIH | 2/19/2025 | $7,506 |
| 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA219342 | ATR Isomerization in Cellular Responses to UV Damage of DNA | 000 | 6 | NIH | 1/2/2025 | -$46,868 |
| 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI165521 | Novel antiviral mechanisms of the interferon system | 000 | 1 | NIH | 10/21/2024 | -$94,462 |
| 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA211904 | Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway | 000 | 6 | NIH | 3/14/2025 | -$191 |
| 2025 | 2022 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI155545 | Anti-inflammatory functions for non-transcriptional IRF3 | 001 | 2 | NIH | 2/12/2025 | -$428,039 |
| 2025 | 2021 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01DK114006 | The Melanocortinergic pathway inglomerular disease | 000 | 6 | NIH | 11/7/2024 | -$1 |
|
 | Issue Date FY: 2024 ( Subtotal = $14,448,701 ) (Continued on the next page) |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AG071332 | PPARG regulates osteocyte bioenergetics and function during aging | 000 | 4 | NIH | 6/4/2024 | $682,204 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA258682 | Targeting eIF4A1 in drug-resistant breast cancer stem-like cells | 000 | 3 | NIH | 7/22/2024 | $388,292 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01AI153496 | Understanding the proviral role for TRAF6 interaction with the viral protease in flavivirus replication and pathogenesis | 000 | 5 | NIH | 4/18/2024 | $386,250 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HL152162 | Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine | 000 | 4 | NIH | 5/31/2024 | $439,948 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA230744 | Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis | 001 | 6 | NIH | 4/15/2024 | $17,672 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA230744 | Influence of bone microenvironment on drug resistance in prostate cancer bone metastasis | 000 | 6 | NIH | 1/11/2024 | $318,077 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 002 | 2 | NIH | 9/10/2024 | $49,202 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | S10OD036266 | Acquisition of a FACSymphony S6 Sorter for the University of Toledo Flow Cytometry Core | 000 | 1 | NIH | 8/26/2024 | $350,000 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03AG080418 | Cerebrovascular endothelial cilia in the pathogenesis and therapy of Alzheimer's disease | 001 | 2 | NIH | 6/21/2024 | $15,177 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R03AG080418 | Cerebrovascular endothelial cilia in the pathogenesis and therapy of Alzheimer's disease | 000 | 2 | NIH | 1/23/2024 | $136,598 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | H1224838 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 00 | 12 | HRSA | 7/1/2024 | $507,781 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 00 | 14 | HRSA | 8/9/2024 | $1,446,948 |
| 2024 | 2024 | University of Toledo | 3000 Arlington Ave | Toledo | OH | 43614-2598 | LUCAS | USA | T03OH008605 | NIOSH Training Project Grant (TPG): Industrial Hygiene - University of Toledo | 00 | 19 | CDC | 5/21/2024 | $86,963 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R21CA277252 | Targeting FASN to eliminate metastatic breast cancer in the brain | 000 | 2 | NIH | 6/13/2024 | $205,853 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01CA276732 | Engineering Exosome for Pancreatic Cancer Targeting Therapies | 000 | 2 | NIH | 8/21/2024 | $487,361 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 001 | 3 | NIH | 5/2/2024 | $47,982 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 000 | 3 | NIH | 1/18/2024 | $479,823 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | R00HL153896 | YAP1, neointima formation, and blood pressure regulation | 001 | 4 | NIH | 6/26/2024 | $24,899 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO, THE | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2595 | LUCAS | USA | R00HL153896 | YAP1, neointima formation, and blood pressure regulation | 000 | 4 | NIH | 12/4/2023 | $224,101 |
| 2024 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-2598 | LUCAS | USA | U01DA054330 | Cross platform analysis of drug targets and toxicity of bath salts | 002 | 3 | NIH | 6/28/2024 | $389,265 |
|